肩袖手术综合加速康复路径可减轻疼痛、减少阿片类药物使用及副作用
该前瞻性配对序贯队列研究纳入140例关节镜肩袖手术患者,比较综合加速康复路径(患者教育、长效神经阻滞、多模式镇痛)与常规护理。路径组术后48小时内活动痛及静息痛更低,阿片类药物用量更少,副作用更少,患者满意度更高。
要点
- 路径组术后第1天活动痛3.3±3.1,对照组5.6±3.0,差异超过最小临床重要差异。
- 路径组0-48小时口服吗啡当量23±28 mg,对照组44±35 mg,前24小时差异最大。
- 路径组恶心、嗜睡等副作用更少,疼痛治疗满意度更高。
核心结论
- 采用包含患者教育、长效神经阻滞和多模式镇痛的路径可改善肩袖术后活动痛,且超过最小临床重要差异。
- 路径组患者导向结局更好,副作用更少。
- 该路径基于长效神经阻滞、多模式镇痛和患者教育,可考虑采用。
研究设计与样本
- 前瞻性配对序贯队列研究,2018年9月至2020年1月纳入281例计划行关节镜日间肩袖手术患者。
- 对照组70例接受常规护理,路径组70例接受路径指导的护理,共140例纳入分析。
- 采用实用性(真实世界)设计,未严格规定对照组治疗,不要求路径组患者接受全部路径组分。
- 证据等级为II级,治疗性研究。
主要发现
- 术后第1天路径组活动痛3.3±3.1,对照组5.6±3.0,平均差-2.7(95%CI -3.7至-1.7),p<0.001。
- 术后第1天路径组静息痛1.9±2.3,对照组4.0±2.9,平均差-2.0(95%CI -2.8至-1.3),p<0.001。
- 0-48小时累积口服吗啡当量路径组23±28 mg,对照组44±35 mg,平均差21(95%CI 10至32),p<0.01。
- 术后第1天路径组睡眠干扰0.5±1.6,对照组2.6±3.3,平均差-2.2(95%CI -3.3至-1.1),p<0.001。
- 术后第1天路径组疼痛治疗满意度9.2±1.7,对照组8.2±2.5,平均差1.0(95%CI 0.3至1.8),p<0.001。
关键数值与推荐
- 主要结局为神经阻滞后0-48小时活动时最严重疼痛的数字评定量表(NRS)评分,范围0-10。
- 样本量计算采用NRS的最小临床重要差异(MCID)为1.3。
- 路径组与对照组主要差异包括:详细患者教育、布比卡因加地塞米松长效神经阻滞、预防性多模式镇痛(术中氯胺酮,术后对乙酰氨基酚、NSAIDs、睡前加巴喷丁,必要时阿片类药物)。
临床怎么用
- 该路径可考虑用于肩袖手术患者,以减轻术后疼痛、减少阿片类药物用量及副作用。
- 路径使用多种镇痛药物,对老年患者可能带来风险,需权衡效应量与潜在风险。
- 需考虑将路径适配本地实践以确保持续实施,且研究仅纳入支持路径的外科医生和麻醉医生,结果可能不同。
局限性
- 采用实用性设计,未严格规定对照组治疗,不要求路径组患者接受全部路径组分。
- 仅纳入支持路径的外科医生和麻醉医生所在中心的患者,结果可能不适用于热情较低的临床医生。
- 路径使用多种镇痛药物,对老年患者可能带来风险,需大规模使用中进一步评估。
- 次要结局术后第2天后对照组失访4例、路径组失访3例(p=0.70)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients often have moderate to severe pain after rotator cuff surgery, despite receiving analgesics and nerve blocks. There are many suggested ways to improve pain after rotator cuff surgery, but the effects of adopting a pathway that includes formal patient education, a long-acting nerve block, and extensive multimodal analgesia are unclear. QUESTIONS/PURPOSES: (1) Does adoption of a clinical pathway incorporating patient education, a long-acting nerve block, and preemptive multimodal analgesia reduce the worst pain during the first 48 hours after surgery compared with current standard institutional practices? (2) Does adoption of the pathway reduce opioid use? (3) Does adoption of the pathway reduce side effects and improve patient-oriented outcomes? METHODS: From September 2018 to January 2020, 281 patients scheduled for arthroscopic ambulatory rotator cuff surgery were identified for this paired sequential prospective cohort study. Among patients in the control group, 177 were identified, 33% (58) were not eligible, for 11% (20) staff was not available, 56% (99) were approached, 16% (29) declined, 40% (70) enrolled, and 40% (70) were analyzed (2% [4] lost to follow-up for secondary outcomes after postoperative day 2). For patients in the pathway cohort, 104 were identified, 17% (18) were not eligible, for 11% (11) staff was not available, 72% (75) were approached, 5% (5) declined, 67% (70) enrolled, and 67% (70) were analyzed (3% [3] lost to follow-up for secondary outcomes after postoperative day 2). No patients were lost to follow-up for primary outcome; for secondary outcomes, four were lost in the control group and three in the pathway group after postoperative day 2 (p = 0.70). The initial 70 patients enrolled received routine care (control group), and in a subsequent cohort, 70 patients received care guided by a pathway (pathway group). Of the 205 eligible patients, 68% (140) were included in the analysis. This was not a study comparing two tightly defined protocols but rather a study to determine whether adoption of a pathway would alter patient outcomes. For this reason, we used a pragmatic (real-world) study design that did not specify how control patients would be treated, and it did not require that all pathway patients receive all components of the pathway. We developed the pathway in coordination with a group of surgeons and anesthesiologists who agreed to apply the pathway as much as was viewed practical for each individual patient. Patients in both groups received a brachial plexus nerve block with sedation. Major differences between the pathway and control groups were: detailed patient education regarding reasonable pain expectations with a goal of reducing opioid use (no formal educational presentation was given to the control), a long-acting nerve block using bupivacaine with dexamethasone (control patients often received shorter-acting local anesthetic without perineural dexamethasone), and preemptive multimodal analgesia including intraoperative ketamine, postoperative acetaminophen, NSAIDs, and gabapentin at bedtime, with opioids as needed (control patients received postoperative opioids but most did not get postoperative NSAIDS and no controls received gabapentin or separate prescriptions for acetaminophen). The primary outcome was the numerical rating scale (NRS) worst pain with movement 0 to 48 hours after block placement. The NRS pain score ranges from 0 (no pain) to 10 (worst pain possible). The minimum clinically important difference (MCID) [12] for NRS that was used for calculation of the study sample size was 1.3 [18], although some authors suggest 1 [13] or 2 [5] are appropriate; if we had used an MCID of 2, the sample size would have been smaller. Secondary outcomes included NRS pain scores at rest, daily opioid use (postoperative day 1, 2, 7, 14), block duration, patient-oriented pain questions (postoperative day 1, 2, 7, 14), and patient and physician adherence to pathway. RESULTS: On postoperative day 1, pathway patients had lower worst pain with movement (3.3 ± 3.1) compared with control patients (5.6 ± 3.0, mean difference -2.7 [95% CI -3.7 to -1.7]; p < 0.001); lower scores were also seen for pain at rest (1.9 ± 2.3 versus 4.0 ± 2.9, mean difference -2.0 [95% CI -2.8 to -1.3]; p < 0.001). Cumulative postoperative opioid use (0-48 hours) was reduced (pathway oral morphine equivalent use was 23 ± 28 mg versus 44 ± 35 mg, mean difference 21 [95% CI 10 to 32]; p < 0.01). The greatest difference in opioid use was in the first 24 hours after surgery (pathway 7 ± 12 mg versus control 21 ± 21 mg, mean difference -14 [95% CI -19 to -10]; p < 0.01). On postoperative day 1, pathway patients had less interference with staying asleep compared with control patients (0.5 ± 1.6 versus 2.6 ± 3.3, mean difference -2.2 [95% CI -3.3 to -1.1]; p < 0.001); lower scores were also seen for interference with activities (0.9 ± 2.3 versus 1.9 ± 2.9, mean difference -1.1 [95% CI -2 to -0.1]; p = 0.03). Satisfaction with pain treatment on postoperative day 1 was higher among pathway patients compared with control patients (9.2 ± 1.7 versus 8.2 ± 2.5, mean difference 1.0 [95% CI 0.3 to 1.8]; p < 0.001). On postoperative day 2, pathway patients had lower nausea scores compared with control patients (0.3 ± 1.1 versus 1 ± 2.1, mean difference -0.7 [95% CI -1.2 to -0.1]; p = 0.02); lower scores were also seen for drowsiness on postoperative day 1 (1.7 ± 2.7 versus 2.6 ± 2.6, mean difference -0.9 [95% CI - 1.7 to -0.1]; p = 0.03). CONCLUSION: Adoption of the pathway was associated with improvement in the primary outcome (pain with movement) that exceeded the MCID. Patients in the pathway group had improved patient-oriented outcomes and fewer side effects. This pathway uses multiple analgesic drugs, which may pose risks to elderly patients, in particular. Therefore, in evaluating whether to use this pathway, clinicians should weigh the effect sizes against the potential risks that may emerge with large scale use, consider the difficulties involved in adapting a pathway to local practice so that pathway will persist, and recognize that this study only enrolled patients among surgeons and the anesthesiologists that advocated for the pathway; results may have been different with less enthusiastic clinicians. This pathway, based on a long-lasting nerve block, multimodal analgesia, and patient education can be considered for adoption. LEVEL OF EVIDENCE: Level II, therapeutic study.
引用
- YaDeau JT, Soffin EM, Tseng A, et al. A Comprehensive Enhanced Recovery Pathway for Rotator Cuff Surgery Reduces Pain, Opioid Use, and Side Effects. Clin Orthop Relat Res. 2021. PMID: 33720071. doi:10.1097/CORR.0000000000001684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。